Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance
COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance – Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Genera
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The earnings release shows modest top‑line growth and a slight decline in adjusted EBITDA, with no change to guidance, suggesting limited immediate price impact.
Market read
Primary relevance is to shareholders and traders of COLL; broader market effect is minimal.
What to watch
The $50M accelerated share repurchase program could support the stock over the next quarter.
Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance – Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year
Product revenues, net increased 3% year-over-year to a record $216.3 million, led by JORNAY PM growth and the first full quarter of AZSTARYS sales under Collegium ownership, but the pain portfolio declined 18%, GAAP and adjusted earnings declined, and adjusted EBITDA declined 9%.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Product revenues, net - three months ended September 30, 2026GAAP | $216.3M | – | 3% increase |
| Product revenues, net - nine months ended September 30, 2026GAAP | $609.7M | – | – |
| Cost of product revenues excluding intangible asset amortization - three months ended September 30, 2026GAAP | $35.58M | – | – |
| Intangible asset amortization in cost of product revenues - three months ended September 30, 2026GAAP | $55.35M | – | – |
| Total cost of product revenues - three months ended September 30, 2026GAAP | $90.92M | – | – |
| Gross profit - three months ended September 30, 2026GAAP | $125.4M | – | – |
| GAAP operating expenses - three months ended September 30, 2026GAAP | $96.7M | – | 44% increase |
| Adjusted operating expenses - three months ended September 30, 2026non-GAAP | $69.4M | – | 25% increase |
| Income from operations - three months ended September 30, 2026GAAP | $28.72M | – | – |
| Net income - three months ended September 30, 2026GAAP | $21.8M | – | – |
| GAAP earnings per share, basic - three months ended September 30, 2026GAAP | $0.69 | – | – |
| GAAP earnings per share, diluted - three months ended September 30, 2026GAAP | $0.60 | – | – |
| Adjusted net income - three months ended September 30, 2026non-GAAP | $75.2M | – | – |
| Adjusted earnings per share - three months ended September 30, 2026non-GAAP | $1.96 | – | – |
| Adjusted EBITDA - three months ended September 30, 2026non-GAAP | $121.6M | – | 9% decrease |
| Gross profit - nine months ended September 30, 2026GAAP | $353.0M | – | – |
| GAAP operating expenses - nine months ended September 30, 2026GAAP | $289.6M | – | – |
| Income from operations - nine months ended September 30, 2026GAAP | $63.32M | – | – |
| Net income - nine months ended September 30, 2026GAAP | $21.20M | – | – |
| GAAP earnings per share, diluted - nine months ended September 30, 2026GAAP | $0.64 | – | – |
| Adjusted net income - nine months ended September 30, 2026non-GAAP | $219.8M | – | – |
| Adjusted earnings per share - nine months ended September 30, 2026non-GAAP | $5.63 | – | – |
| Adjusted EBITDA - nine months ended September 30, 2026non-GAAP | $339.3M | – | – |
| Cash from operations - three months ended September 30, 2026GAAP | $86.5M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| JORNAY PMJORNAY PM prescriptions grew 16% year-over-year and nearly 33,000 healthcare providers wrote JORNAY PM prescriptions, up 19% year-over-year. | $51.9M | – | 24% |
| AZSTARYSThis was the first full quarter of sales under Collegium ownership; prescriptions grew nearly 2% compared to the quarter ended September 30, 2025. | $26.5M | – | – |
| Pain portfolioThe portfolio includes Belbuca, Xtampza ER and the Nucynta Franchise. | $138M | – | down 18% |
| BelbucaBelbuca was the largest reported pain-portfolio product by quarterly net revenue. | $57.7M | – | down 1% |
| Xtampza ERXtampza ER net revenue declined year-over-year. | $45.8M | – | down 9% |
| Nucynta FranchiseRevenue included $4.2 million from Hikma Pharmaceuticals USA Inc. for the sale of authorized generic versions of Nucynta and Nucynta ER. | $30.8M | – | down 44% |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Full-year 2026 outlook
- RevenueProduct Revenues, Net $825 to $855 million
- NoteJORNAY PM Revenue, Net $190 to $200 million
- NoteAZSTARYS Revenue, Net $65 to $75 million
- NoteAdjusted EBITDA $445 to $470 million
Capital returns
- Announced a $50 million accelerated share repurchase program in Q3 2026.
- The final settlement of the accelerated share repurchase program is expected to be completed in the fourth quarter of 2026.
What drove it
- Expanded commercial efforts supported ADHD demand heading into the back-to-school season.
- JORNAY PM reached record revenues, prescriptions and prescriber adoption.
- AZSTARYS generated its first full quarter of sales under Collegium ownership.
- ADHD franchise revenue contributed more than 36% of total revenue.
- The company reaffirmed full-year 2026 guidance for Product Revenues, Net, JORNAY PM Revenue, Net, AZSTARYS Revenue, Net and Adjusted EBITDA.
Concerns
- Pain portfolio net revenues were down 18% year-over-year, including a 44% decline in Nucynta Franchise net revenue.
- GAAP operating expenses increased 44% year-over-year and adjusted operating expenses increased 25% year-over-year.
- GAAP net income, adjusted net income and adjusted EBITDA were lower than in the 2025 Quarter.
- The company identified risks related to realizing anticipated benefits of the AZSTARYS acquisition, commercialization, competition, reimbursement, supply, litigation and regulatory compliance.
What to watch
- Completion of the $50 million accelerated share repurchase program in the fourth quarter of 2026.
- JORNAY PM prescription and prescriber growth following expanded commercial efforts.
- AZSTARYS revenue and prescription performance following its first full quarter under Collegium ownership.
- Pain portfolio performance, particularly the Nucynta Franchise.
- Delivery against reaffirmed full-year 2026 Product Revenues, Net and adjusted EBITDA guidance.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $144.8 million at September 30, 2026.
- Cash and cash equivalents were $144,797 (in thousands) at September 30, 2026, compared to $231,252 (in thousands) at December 31, 2025.
- Marketable securities were — at September 30, 2026, compared to $155,427 (in thousands) at December 31, 2025.
- Term notes payable were $842,507 (in thousands) at September 30, 2026, compared to $571,112 (in thousands) at December 31, 2025.
- Convertible senior notes were $238,996 (in thousands) at September 30, 2026, compared to $238,213 (in thousands) at December 31, 2025.
- Accounts receivable, net were $310,785 (in thousands) at September 30, 2026, compared to $211,328 (in thousands) at December 31, 2025.
- Inventory was $88,202 (in thousands) at September 30, 2026, compared to $40,912 (in thousands) at December 31, 2025.
- Total assets were $2,095,936 (in thousands) at September 30, 2026, compared to $1,656,834 (in thousands) at December 31, 2025.
- Shareholders’ equity was $296,437 (in thousands) at September 30, 2026, compared to $301,675 (in thousands) at December 31, 2025.
Analysis
Collegium reported record quarterly Product revenues, net of $216.3 million, up 3% year-over-year from $209.4 million. The growth profile was concentrated in ADHD: JORNAY PM generated $51.9 million, up 24%, while AZSTARYS contributed $26.5 million in its first full quarter under Collegium ownership. Management reported that the ADHD franchise contributed more than 36% of total revenue.
The legacy pain portfolio remained a material offset. Pain portfolio net revenues were $138.0 million, down 18% year-over-year. Belbuca declined 1% to $57.7 million and Xtampza ER declined 9% to $45.8 million, while the Nucynta Franchise declined 44% to $30.8 million. The Nucynta result included $4.2 million from Hikma for authorized generic versions of Nucynta and Nucynta ER.
Profitability declined despite revenue growth. Gross profit was $125,418 (in thousands), versus $129,171 (in thousands) in the prior-year quarter. GAAP operating expenses increased 44% to $96.7 million, and adjusted operating expenses increased 25% to $69.4 million. GAAP net income was $21.8 million, compared with $31.5 million, while adjusted net income was $75.2 million, compared with $87.3 million. Adjusted EBITDA declined 9% to $121.6 million.
Cash from operations was $86.5 million for the quarter, and cash, cash equivalents and marketable securities were $144.8 million at quarter-end. Term notes payable were $842,507 (in thousands), versus $571,112 (in thousands) at December 31, 2025. The company announced a $50 million accelerated share repurchase program in Q3 2026 and expects final settlement in the fourth quarter of 2026.
Management reaffirmed its full-year 2026 outlook: Product Revenues, Net of $825 to $855 million, JORNAY PM Revenue, Net of $190 to $200 million, AZSTARYS Revenue, Net of $65 to $75 million, and adjusted EBITDA of $445 to $470 million. The principal reported operating markers are the sustainability of JORNAY PM growth, AZSTARYS prescription momentum, and the degree to which ADHD growth can offset pain-portfolio declines and higher operating expenses.
Management, verbatim
We continued to see strong demand across our ADHD portfolio, supported by expanded commercial efforts heading into the back-to-school season. JORNAY PM reached record revenues, prescriptions and prescriber adoption, with quarterly net revenue growing 24% year-over-year.
Vikram Karnani, President and Chief Executive Officer
Additionally, in the first full quarter of Collegium’s ownership of AZSTARYS, revenues exceeded $26.5 million supported by nearly 2% prescription growth year-over-year.
Vikram Karnani, President and Chief Executive Officer
We generated a record $216.3 million in quarterly net revenue and $121.6 million in adjusted EBITDA, with our ADHD franchise now contributing more than 36% of total revenue.
Colleen Tupper, Chief Financial Officer
Not in the filing
stated, not guessed- Prior-quarter comparisons were not reported for the financial metrics or product revenues.
- GAAP gross margin and non-GAAP gross margin were not reported.
- Free cash flow was not reported.
- Cash from operations for the comparable prior-year quarter was not reported.
- A prior earnings-release outlook was not provided, so no comparison of actual results with prior guidance is available.
- A reconciliation of full-year 2026 adjusted EBITDA guidance to the most directly comparable forward-looking GAAP measure was not provided.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) filed a Form 8‑K reporting its third‑quarter 2026 financial results and reaffirmed its full‑year guidance.
Ticker impact
COLL reaffirmed its full-year 2026 guidance after reporting Q3 results with record revenue of $216.3M.
neutral pressure as investors digest results without guidance change
The company posted modest revenue growth and reaffirmed guidance, offering no new catalyst for directional moves.
Market effects
ADHD and pain‑management segments show mixed performance, but no sector‑wide shift.
US biotech sector may see limited impact as guidance unchanged.
Minimal, limited to investors tracking Collegium.
Counterpoint
If investors expected a guidance raise, the reaffirmation could be viewed as a disappointment, prompting a short bias.
Key entities
- companyCollegium Pharmaceutical, Inc.
Biopharmaceutical company reporting Q3 2026 results.



